as 06-18-2025 11:38am EST
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
Founded: | 2011 | Country: | United States |
Employees: | N/A | City: | WEST CONSHOHOCKEN |
Market Cap: | 6.1B | IPO Year: | N/A |
Target Price: | $420.63 | AVG Volume (30 days): | 306.7K |
Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -17.97 | EPS Growth: | N/A |
52 Week Low/High: | $200.63 - $377.46 | Next Earning Date: | 08-06-2025 |
Revenue: | $317,383,000 | Revenue Growth: | N/A |
Revenue Growth (this year): | 286.17% | Revenue Growth (next year): | 64.17% |
MDGL Breaking Stock News: Dive into MDGL Ticker-Specific Updates for Smart Investing
GlobeNewswire
20 hours ago
Simply Wall St.
6 days ago
GlobeNewswire
16 days ago
Yahoo Finance
18 days ago
The Guardian
18 days ago
Yahoo Finance Video
18 days ago
Reuters
18 days ago
USA TODAY
18 days ago
The information presented on this page, "MDGL Madrigal Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.